Table of Contents
What treatment programs document, accommodate, and follow through on should reflect the needs of the person seeking care.
A person seeking help for cocaine or methamphetamine use may first need sleep, food, relief from frightening symptoms, or someone willing to listen. Stopping use may be their goal, or they may not be ready to have that conversation.
Treatment programs must respond to the person in front of them while assessing risk and providing effective care.
That requires trust. For providers, the practical question is how to sustain that trust throughout an entire episode of care: the first conversation, the treatment plan, the response to a missed appointment, and the transition to another clinician or program.
Respectful language matters. So does whether the next person reviewing the chart can understand what happened and what needs attention.
Ask what stimulant use is doing for the person
An assessment needs more than the substance, frequency, and date of last use. It also needs the person’s account of why they use and what they want to change.
Someone may describe using stimulants for pleasure, wakefulness, sexual experiences, or relief from distress. The ASAM/AAAP guideline specifically recommends understanding these motivations when discussing risks and alternatives.
Useful questions include:
- What do you get from using?
- What has become difficult or frightening?
- What would you like help with today?
These questions help identify what a treatment plan must address. If someone uses to stay awake or feel connected, advice to stop leaves an important question unanswered. What will help meet that need instead?
Keep the person’s priorities visible as treatment progresses. A goal discussed at intake should inform subsequent care, with flexibility to adjust as the person’s needs and circumstances change.
Write a record the next clinician can use
Person-first language helps distinguish a person from a diagnosis. NIDA recommends using terms such as “person with a substance use disorder” and medically accurate descriptions of test results, rather than “clean” or “dirty.” People may choose different language for themselves; clinicians can respect that choice while using precise, professional language.
The same principle applies to behavioral descriptions.
Words such as “difficult,” “aggressive,” or “noncompliant” can omit the information needed to understand an encounter. What did the person do? What did they report? What was offered, and how did they respond?
For example, an illustrative note might describe a person pacing, reporting that someone is following them, and declining to enter a crowded group room. That gives the next clinician more to work with than a judgment about their attitude.
Specificity also means clearly documenting threats or unsafe behavior when they occur. Respectful care and accurate safety documentation go hand in hand.
A useful record distinguishes what the patient reported, what staff observed, and what the clinician concluded. It clarifies whether a symptom is current, historical, improving, or unresolved.
For program leaders, this is a practical quality question: can someone unfamiliar with the patient understand the clinical reasoning and the next step?
Match early expectations to the person’s condition
Stimulant withdrawal can involve profound fatigue, increased sleep, increased appetite, depressed mood, and difficulty concentrating. SAMHSA describes a course that varies by the substance and pattern of use.
A person recovering from prolonged wakefulness may struggle to participate in a full schedule right away. Programs should recognize that limitation before treating it as unwillingness to engage.
Rest, nutrition, hydration, and an adjusted schedule may be appropriate components of care following assessment.
However, difficulty waking someone should never be automatically attributed to a stimulant “crash.” Inability to awaken and slow or abnormal breathing can indicate an opioid overdose and require emergency action.
Assessment must continue beyond the first few days. The ASAM/AAAP guideline warns that suicide risk may rise as intoxication wanes and acute withdrawal begins, and that some mood, sleep, and psychiatric symptoms can persist for weeks or months.
Discharge planning should reflect the person’s current symptoms and support needs. Completing a short stay alone does not establish readiness for an unsupported transition.
Recognize distress and medical danger together
“Overamping” is a term used to describe harmful stimulant effects that can include severe anxiety, paranoia, hallucinations, overheating, cardiovascular symptoms, and other serious complications. People may describe these experiences without calling them an overdose.
Symptom-based questions can make the conversation more productive:
“Have you ever used and then felt dangerously hot, experienced chest pain, or started hearing voices?”
“What happened, and what help did you receive?”
When someone is frightened or experiencing paranoia, staff can acknowledge the distress without confirming the belief. One possible response is:
“That sounds frightening. Would you be willing to move somewhere quieter while we work out how to help?”
Verbal de-escalation can support care, but it must not delay urgent treatment when severe complications are developing.
Programs need clear escalation procedures and staff who know when an encounter requires medical support. Chest pain, seizures, severe overheating, or immediate danger require emergency assessment.
Psychiatric follow-up matters, too. Persistent or recurring symptoms require evaluation rather than assuming everything will resolve once stimulant use stops. SAMHSA describes stimulant-associated psychosis that may persist or recur after the immediate episode.
Make effective treatment practical to deliver
Trust should help people access evidence-supported treatment.
The ASAM/AAAP guideline recommends contingency management as a primary component of stimulant use disorder treatment, alongside other psychosocial care. It identifies community reinforcement, cognitive behavioral therapy, and the Matrix Model as preferred approaches to use alongside contingency management. The guideline also discusses off-label medication options for selected patients.
Contingency management uses tangible incentives to reinforce a defined, verified treatment-related behavior.
For operators, implementation deserves as much attention as the clinical recommendation. A program needs to specify the target behavior, how it will be verified, how incentives will be delivered and recorded, and who will oversee the process. Funding requirements also matter. SAMHSA’s advisory sets out guardrails for contingency management and outlines the applicable SAMHSA grants.
Patients should understand the arrangement, and staff should be able to implement it consistently.
Keep care available before abstinence
Someone who continues to use stimulants can still benefit from healthcare services.
Overdose prevention is one example. The CDC advises that people using cocaine or methamphetamine may also encounter fentanyl. Naloxone reverses opioid overdoses; it does not reverse stimulant toxicity. That distinction should be part of clear, practical education.
Programs should also recognize meaningful changes short of abstinence. A 2024 analysis pooled data from 13 randomized trials involving 2,062 people seeking treatment for cocaine or methamphetamine use disorder. Reduced use was linked to improvements in craving, depression severity, and psychosocial functioning, though these associations were generally stronger with abstinence. The findings support measuring progress beyond abstinence alone; they do not establish that continued use is safe.
That gives teams a reason to track both substance use and the person’s broader goals. Are symptoms improving? Is the person returning for care? What remains difficult, and what should the plan change?
Make follow-through visible
A handoff that leaves the next clinician without essential context can undermine trust.
Before a transfer or discharge, teams should be able to identify the person’s current priorities, unresolved concerns, agreed-upon next steps, and the responsible party for follow-up.
The same discipline applies after a missed appointment. Before closing an episode of care, consider what is known about the missed visit, what outreach is appropriate, and how the person can return to care.
For leaders, these are concrete ways to assess whether a program’s commitment to person-centered care extends to daily practice.
Does the record explain the patient’s needs? Does the plan address them? Can the next clinician see what requires attention?
Treating stimulant use disorder requires clinical skill, patience, and effective interventions. Trust helps make those interventions accessible. Consistent follow-through gives people a reason to return.
This article is for educational purposes only and does not replace individualized medical assessment, treatment, or training from qualified, licensed professionals.
FAQs
Which treatments are effective for stimulant use disorder?
Contingency management has the strongest evidence and is recommended by ASAM and AAAP as a primary treatment component. Other approaches include cognitive behavioral therapy, community reinforcement, and the Matrix Model. Medication may also be considered based on individual needs.
What is contingency management for stimulant use disorder?
Contingency management uses tangible incentives to reinforce specific, verified behaviors, such as attending treatment or submitting a stimulant-negative drug test. Effective programs use clear rules and consistent verification, reinforcement, and recordkeeping.
What are common stimulant withdrawal symptoms?
Stimulant withdrawal can include fatigue, increased sleep and appetite, depressed mood, anxiety, and difficulty concentrating. Symptoms vary, and some may persist beyond the initial withdrawal period, making ongoing assessment important.
Can someone benefit from treatment before discontinuing stimulant use?
Yes. Care can address immediate health concerns, reduce risks, and help someone work toward their goals. Research has linked reduced stimulant use to improvements in craving, depression severity, and psychosocial functioning, although continued use still carries risks.
Why does nonjudgmental language matter in addiction treatment?
Nonjudgmental language supports respectful communication and helps clinicians describe symptoms and behavior accurately. Person-first terms and specific observations provide the next clinician with more useful information than labels such as “addict” or “difficult.”
Does naloxone reverse a stimulant overdose?
Naloxone does not reverse stimulant toxicity. It reverses opioid overdoses and can help when opioids, such as fentanyl, are also involved. A suspected overdose requires emergency help, including when someone cannot be awakened or has slow or abnormal breathing.